^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersBIOMARKER:
HER-2 overexpression
i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
Related tests:
1d
HER2-dependent paraptosis and ferroptosis induction by cannabidiol in breast cancer cells. (PubMed, Biochim Biophys Acta Mol Basis Dis)
These findings support a model in which CBD downregulates HER2 and, in a HER2-dependent context, promotes paraptosis and ferroptosis. In addition, docking and molecular dynamics analyses suggested a potential interaction between CBD and HER2, providing mechanistic insights into possible molecular recognition relevant to HER2-positive breast cancer.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • ATF4 (Activating Transcription Factor 4)
|
HER-2 positive • HER-2 overexpression • HER-2 negative • HER-2 positive + HER-2 overexpression
2d
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer (clinicaltrials.gov)
P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase)
|
HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
|
Herceptin (trastuzumab) • Tukysa (tucatinib)
2d
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC (clinicaltrials.gov)
P=N/A, N=60, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • HER-2 mutation
|
Perjeta (pertuzumab) • trastuzumab rezetecan (SHR-A1811)
3d
A single-center, single-arm, exploratory clinical trial investigating the tolerance, safety, and efficacy of xg0201 for her2-positive breast cancer with brain metastases (ChiCTR2500105266)
P=N/A, N=3, Suspended, The Third Affiliated Hospital of Zhengzhou University; The Third Affiliated Hospital of Zhengzhou University | Recruiting --> Suspended
Trial suspension
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 positive + HER-2 overexpression
3d
A study on the treatment of advanced gastric/gastroesophageal junction adenocarcinoma with docetaxel for injection (albumin-bound type) combined with oxaliplatin and 5-FU/LV (ADOF) (ChiCTR2500112147)
P=N/A, N=12, Not yet recruiting, Fujian Cancer Hospital; CSPC Zhongqi Pharmaceutical Technology Co., Ltd.
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability)
|
PD-L1 expression • MSI-H/dMMR • HER-2 overexpression
|
5-fluorouracil • oxaliplatin • albumin-bound docetaxel (CPO100)
3d
Safety Study of the Combination Regimen Based on HuA21 Monoclonal Antibody for the Treatment of Advanced HER2-overexpressing Solid Tumors (ChiCTR2500112039)
P=N/A, N=90, Not yet recruiting, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
New trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression
|
Herceptin (trastuzumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel
3d
A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping (ChiCTR2500111407)
P=N/A, N=55, Not yet recruiting, Fuzhou University Affiliated Provincial Hospital; Fuzhou University Affiliated Provincial Hospital
New trial
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MET (MET proto-oncogene, receptor tyrosine kinase) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • RET (Ret Proto-Oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • NRG1 (Neuregulin 1) • VEGFA (Vascular endothelial growth factor A) • RNF43 (Ring Finger Protein 43) • TYK2 (Tyrosine Kinase 2) • NTRK (Neurotrophic receptor tyrosine kinase)
|
BRAF V600E • KRAS mutation • EGFR mutation • MSI-H/dMMR • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • BRAF V600 • MET amplification • RET fusion • FGFR2 mutation • PALB2 mutation • FGFR2 fusion • MET mutation • IDH mutation + BRAF V600E • IDH mutation + NTRK fusion
3d
A prospective, single-center, exploratory phase II clinical study of QL1706 combined with chemotherapy in the treatment of previously untreated advanced or metastatic gastric cancer or gastroesophageal junction cancer. (ChiCTR2600116087)
P2, N=32, Not yet recruiting, Beijing Friendship Hospital, Capital Medical University; Beijing Friendship Hospital, Capital Medical University
New P2 trial
|
HER-2 overexpression • HER-2 amplification
|
oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • Qibeian (iparomlimab/tuvonralimab)
3d
A randomized, controlled, multicenter clinical study of SHR-A1811 in combination with bevacizumab for second-line treatment of metastatic colorectal cancer. (ChiCTR2600116782)
P2, N=80, Not yet recruiting, Peking Union Medical College Hospital; Peking Union Medical College Hospital
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene)
|
HER-2 overexpression • HER-2 expression
|
Avastin (bevacizumab) • 5-fluorouracil • irinotecan • trastuzumab rezetecan (SHR-A1811) • leucovorin calcium
3d
Ipalolitovorizumab ( QL1706 ) combined with chemotherapy in the treatment of previous non-lineage Prospective, single-center treatment of advanced or metastatic gastric cancer or gastroesophageal junction cancer. Central, exploratory phase II clinical study (ChiCTR2600116407)
P2, N=32, Not yet recruiting, Beijing Friendship Hospital ,Capital Medical University; Beijing Friendship Hospital ,Capital Medical University
New P2 trial
|
HER-2 overexpression • HER-2 negative
|
Qibeian (iparomlimab/tuvonralimab)
3d
Exploratory Study of Disitamab Vedotin Combination Therapy in Advanced Gastrointestinal Tumors with HER2 Overexpression or Amplification (ChiCTR2500114011)
P2, N=90, Not yet recruiting, The First Affiliated Hospital of Henan University of Chinese Medicine; The First Affiliated Hospital of Henan University of Chinese Medicine
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 overexpression • HER-2 amplification • RAS wild-type • HER-2 positive + RAS wild-type
|
Erbitux (cetuximab) • Perjeta (pertuzumab) • Lenvima (lenvatinib) • Aidixi (disitamab vedotin)
3d
SHR-A1811 plus QL1706 versus standard therapy as first-line treatment for locally advanced or metastatic HER2-overexpressing non-small cell lung cancer: an open-label, single-arm, phase II clinical trial (ChiCTR2500114106)
P2, N=39, Not yet recruiting, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
New P2 trial
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
HER-2 positive • EGFR mutation • HER-2 overexpression • HER-2 mutation • ALK mutation • HER-2 positive + HER-2 overexpression
|
trastuzumab rezetecan (SHR-A1811) • Qibeian (iparomlimab/tuvonralimab)
Share via
